Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabisol CBD
- Development stage
- Unknown
- Lead developer
- PHCANN International
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cannabisol CBD is a plant-derived cannabidiol (CBD) product developed and marketed by PHCANN International as part of its medicinal cannabis portfolio. Unlike traditional pharmaceutical candidates in a clinical pipeline, Cannabisol CBD is a commercialized product available in various concentrations, including Cannabisol CBD 10, 20, and 30. As a phytocannabinoid, its mechanism of action involves complex interactions with the endocannabinoid system, notably acting as a negative allosteric modulator of the Cannabinoid receptor 1 (CB1) and an antagonist of the Cannabinoid receptor 2 (CB2). It also modulates non-cannabinoid targets such as the 5-HT1A serotonin receptor and TRPV1 ion channels. The product is typically administered as an oral solution for the management of conditions where medicinal cannabis is indicated, such as chronic pain, inflammation, and neurological disorders.
- Brand names
- Cannabisol CBDCannabisol CBD 10Cannabisol CBD 20Cannabisol CBD 30
- Other names
- Cannabisol CBD 20
02
Targets
CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Cannabisol CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cannabisol CBD.